These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34903151)

  • 21. Tributyltin inhibits osteoblastic activity and disrupts calcium metabolism through an increase in plasma calcium and calcitonin levels in teleosts.
    Suzuki N; Tabata MJ; Kambegawa A; Srivastav AK; Shimada A; Takeda H; Kobayashi M; Wada S; Katsumata T; Hattori A
    Life Sci; 2006 Apr; 78(21):2533-41. PubMed ID: 16318860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro.
    Tuukkanen J; Väänänen HK
    Calcif Tissue Int; 1986 Feb; 38(2):123-5. PubMed ID: 3006888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RANKL, Ephrin-Eph and Wnt10b are key intercellular communication molecules regulating bone remodeling in autologous transplanted goldfish scales.
    Tazaki Y; Sugitani K; Ogai K; Kobayashi I; Kawasaki H; Aoyama T; Suzuki N; Tabuchi Y; Hattori A; Kitamura KI
    Comp Biochem Physiol A Mol Integr Physiol; 2018 Nov; 225():46-58. PubMed ID: 29886255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity.
    Costa-Rodrigues J; Reis S; Teixeira S; Lopes S; Fernandes MH
    FEBS J; 2013 Oct; 280(20):5052-64. PubMed ID: 23937530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
    Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
    Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psoralen accelerates bone fracture healing by activating both osteoclasts and osteoblasts.
    Zhang T; Han W; Zhao K; Yang W; Lu X; Jia Y; Qin A; Qian Y
    FASEB J; 2019 Apr; 33(4):5399-5410. PubMed ID: 30702934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteoblastogenesis and osteoprotection enhanced by flavonolignan silibinin in osteoblasts and osteoclasts.
    Kim JL; Kang SW; Kang MK; Gong JH; Lee ES; Han SJ; Kang YH
    J Cell Biochem; 2012 Jan; 113(1):247-59. PubMed ID: 21898547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two osteoclastic markers expressed in multinucleate osteoclasts of goldfish scales.
    Azuma K; Kobayashi M; Nakamura M; Suzuki N; Yashima S; Iwamuro S; Ikegame M; Yamamoto T; Hattori A
    Biochem Biophys Res Commun; 2007 Oct; 362(3):594-600. PubMed ID: 17765203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Na+/H+ antiporter is the primary proton transport system used by osteoclasts during bone resorption.
    Hall TJ; Chambers TJ
    J Cell Physiol; 1990 Feb; 142(2):420-4. PubMed ID: 2154508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of low-intensity pulsed ultrasound on osteoclasts: Analysis with goldfish scales as a model of bone.
    Hanmoto T; Tabuchi Y; Ikegame M; Kondo T; Kitamura KI; Endo M; Kobayashi I; Mishima H; Sekiguchi T; Urata M; Seki A; Yano S; Hattori A; Suzuki N
    Biomed Res; 2017; 38(1):71-77. PubMed ID: 28239034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct and indirect actions of fibroblast growth factor 2 on osteoclastic bone resorption in cultures.
    Kawaguchi H; Chikazu D; Nakamura K; Kumegawa M; Hakeda Y
    J Bone Miner Res; 2000 Mar; 15(3):466-73. PubMed ID: 10750561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteoblastic activity and estrogenic response in the regenerating scale of goldfish, a good model of osteogenesis.
    Yoshikubo H; Suzuki N; Takemura K; Hoso M; Yashima S; Iwamuro S; Takagi Y; Tabata MJ; Hattori A
    Life Sci; 2005 Apr; 76(23):2699-709. PubMed ID: 15792836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term omeprazole treatment does not influence biochemical parameters of bone turnover in children.
    Kocsis I; Arató A; Bodánszky H; Szönyi L; Szabó A; Tulassay T; Vásárhelyi B
    Calcif Tissue Int; 2002 Aug; 71(2):129-32. PubMed ID: 12200646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effect of cadmium on osteoblastic cells and osteoclastic cells.
    Iwami K; Moriyama T
    Arch Toxicol; 1993; 67(5):352-7. PubMed ID: 8368944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel bioactivity of phosvitin in connective tissue and bone organogenesis revealed by live calvarial bone organ culture models.
    Liu J; Czernick D; Lin SC; Alasmari A; Serge D; Salih E
    Dev Biol; 2013 Sep; 381(1):256-75. PubMed ID: 23791550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vasoactive intestinal peptide regulates osteoclast activity via specific binding sites on both osteoclasts and osteoblasts.
    Lundberg P; Lie A; Bjurholm A; Lehenkari PP; Horton MA; Lerner UH; Ransjö M
    Bone; 2000 Dec; 27(6):803-10. PubMed ID: 11113391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mechanism of action of omeprazole--a survey of its inhibitory actions in vitro.
    Wallmark B; Lorentzon P; Larsson H
    Scand J Gastroenterol Suppl; 1985; 108():37-51. PubMed ID: 2988109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Both mercury and cadmium directly influence calcium homeostasis resulting from the suppression of scale bone cells: the scale is a good model for the evaluation of heavy metals in bone metabolism.
    Suzuki N; Yamamoto M; Watanabe K; Kambegawa A; Hattori A
    J Bone Miner Metab; 2004; 22(5):439-46. PubMed ID: 15316864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases.
    Mattsson JP; Väänänen K; Wallmark B; Lorentzon P
    Biochim Biophys Acta; 1991 Jun; 1065(2):261-8. PubMed ID: 1647821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
    de Korwin JD; Ducrotté P; Vallot T
    Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.